Previous 10 | Next 10 |
--Product has potential to achieve greater inhibition of estrogen receptors and better outcomes for patients with ER-positive breast cancer-- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the Company has commenced d...
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 31 st Annual Piper Jaffray Healthcare Conference as follows: The...
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Douglas L. Braunstein is stepping down from the Company’s Board of Directors, effective November 14, 2019. Mr. Braunstein joined the Board in 2016 and served on its Co...
Image source: The Motley Fool. Eagle Pharmaceuticals Inc (NASDAQ: EGRX) Q3 2019 Earnings Call Nov 12, 2019 , 8:30 a.m. ET Operator Continue reading
Eagle Pharmaceuticals, Inc. (EGRX) Q3 2019 Earnings Conference Call November 12, 2019 8:30 A.M. ET Company Participants Lisa Wilson - Investor Relations Scott Tarriff - Chief Executive Officer Pete Meyers - Chief Financial Officer Conference Call Participants Brandon Folke...
Eagle Pharmaceuticals (NASDAQ: EGRX ): Q3 Non-GAAP EPS of $0.26 misses by $0.17 ; GAAP EPS of -$0.17 misses by $0.18 . Revenue of $41.14M (-19.9% Y/Y) misses by $4.3M . Press Release More news on: Eagle Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, ...
-- Net loss of $0.17 per basic and diluted share and adjusted non-GAAP net income of $0.27 per basic and $0.26 per diluted share in Q3 2019 -- -- Plan to initiate a clinical trial in December for Eagle’s innovative fulvestrant program, which has the potential to result in greater...
Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today provided an update on the Company’s program for RYANODEX ® (dantrolene sodium for injectable suspension) for the treatment of exertional heat stroke (“EHS”). Eagl...
Eagle Pharmaceuticals, Inc. ("Eagle" or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2019 third quarter financial results on Tuesday, November 12, 2019, before the market opens. Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief...
Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX) today announced that its marketing partner SymBio Pharmaceuticals Limited (“SymBio”) has submitted a New Drug Application (“NDA”) for TREAKISYM ready-to-dilute (ȁ...
News, Short Squeeze, Breakout and More Instantly...
Eagle Pharmaceuticals Inc. Company Name:
EGRX Stock Symbol:
NASDAQ Market:
Eagle Pharmaceuticals Inc. Website:
2024-07-27 11:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-17 12:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-07 19:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...